SIGA TECHNOLOGIES, INC. (OTCMKTS:SIGA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
Technologies, Inc., a Delaware corporation (SIGA), appointed Dr.
Phillip L. Gomez, SIGAs Chief Executive Officer, to fill a
vacancy on the Board created by the increase in the size of the
Board described in Item 5.03 below. Dr. Gomez, 49, will serve a
term through the date of the next annual meeting of SIGAs
stockholders or until his earlier resignation or removal. Dr.
Gomez will not receive additional compensation in connection with
his service on the Board.
| Item 5.03. |
Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year. |
Amendment) to Section 3.1 of the amended and restated by-laws of
SIGA increasing the minimum size of the Board from one member to
three members and maximum size of the Board from nine members to
twelve. The Amendment took effect immediately upon its adoption
by the Board.
entirety by reference to the Amendment filed as Exhibit 3.1
hereto and incorporated herein by reference.
| Item 9.01. |
Financial Statements and Exhibits.
|
| (c) |
Exhibits
|
|
Exhibit No.
|
Description
|
|
|
3.1
|
Amendment to the Amended and Restated By-laws of SIGA
Technologies, Inc. |
About SIGA TECHNOLOGIES, INC. (OTCMKTS:SIGA)
SIGA Technologies, Inc. (SIGA) is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. Tecovirimat is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). Tecovirimat is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. Tecovirimat has Orphan Drug designation for both the treatment and prevention of smallpox, and the treatment of orthopoxvirus infections (vaccinia, variola, monkeypox and cowpox). The Company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture Tecovirimat. The Company also has a lead pre-clinical drug candidate with activity against approximately four serotypes of the dengue virus. SIGA TECHNOLOGIES, INC. (OTCMKTS:SIGA) Recent Trading Information
SIGA TECHNOLOGIES, INC. (OTCMKTS:SIGA) closed its last trading session down -0.11 at 2.86 with shares trading hands.